AMI Eyes Polynucleotide

1 review for AMI Eyes Polynucleotide

1. 

   Rated 5 out of 5

   Dr. Zeshan Ahmed (Chief Aesthetic Physician at GoldyZ) – June 28, 2026

   AMI Eyes is a specialized polynucleotide (PN)-based tissue biostimulator designed for the delicate periorbital
   region. Derived from highly purified salmon DNA, it offers a regenerative approach to under-eye rejuvenation
   by stimulating cellular repair, neocollagenesis, and extracellular matrix remodeling. In my clinical practice, it
   has proven particularly valuable for patients presenting with thin, crepey under-eye skin, vascular dark
   circles, fine lines, and dehydration—concerns where traditional hyaluronic acid (HA) fillers carry higher risks
   of edema, Tyndall effect, or unnatural volumization.

   Key Clinical Findings: With a standard protocol of 2-3 sessions spaced 3-4 weeks apart, patients typically
   experience measurable improvements in skin elasticity, hydration, brightness, and texture. Results develop
   progressively over 4-12 weeks and are maintained for 6-12 months. The safety profile is excellent, with
   minimal downtime and low incidence of adverse events when administered by trained injectors.

   COMPOSITION AND MECHANISM OF ACTION

   Product Specifications

   AMI Eyes is supplied as a sterile, ready-to-use 2 mL syringe containing 1% polynucleotides (20 mg total;
   approximately 10 mg/mL). The active ingredient consists of highly purified, low-molecular-weight DNA
   fragments extracted from salmon milt (sperm). These polynucleotides are biocompatible with human tissue
   due to structural similarity with human DNA.

   Mechanism of Action

   • Cellular Regeneration: Provides exogenous nucleotides that support DNA repair and salvage
   pathways in damaged or aging cells.
   • Fibroblast Stimulation: Acts as an agonist at adenosine A2A receptors, upregulating fibroblast activity
   and promoting synthesis of collagen types I & III and elastin.
   • Angiogenesis & Microcirculation: Enhances vascular endothelial growth factor (VEGF) expression,
   improving nutrient delivery and oxygenation in the thin periorbital dermis.
   • Anti-Inflammatory Effects: Modulates inflammatory cytokines, beneficial for post-procedural healing
   and chronic low-grade inflammation in photoaged skin.

   CLINICAL INDICATIONS

   AMI Eyes is indicated for aesthetic improvement of the periorbital area in adult patients exhibiting signs of
   cutaneous aging or photo-damage. Primary indications include:
   • Dark Circles (Vascular / Thin-Skin Type): Improvement in brightness and reduction of shadowing
   through enhanced dermal thickness and microcirculation.
   • Fine Lines & Wrinkles: Particularly effective for dynamic and static rhytids in the crow’s feet and lower
   eyelid regions.
   • Crepey / Atrophic Skin: Restoration of dermal thickness and elasticity in patients with translucent or
   parchment-like under-eye skin.
   • Dehydration & Dullness: Marked improvement in skin hydration and radiance via matrix remodeling.
   • Mild Puffiness / Fatigue Appearance: Reduction in tired-looking eyes through better tissue quality and
   reduced inflammation.
   • Adjunct to Other Treatments: Excellent pre-treatment for HA tear trough filler or as maintenance
   following other modalities to optimize skin quality.
   Ideal Patient Profile: Age 28-55, good skin quality baseline, realistic expectations, commitment to a course
   of treatment, and preference for natural, regenerative outcomes over instant volumization.

   EFFICACY AND CLINICAL OUTCOMES

   While large-scale, brand-specific randomized controlled trials for AMI Eyes are not yet widely published
   (common in the aesthetic device sector), the underlying polynucleotide technology benefits from a growing
   body of high-quality evidence. Split-face and randomized studies on PN/PDRN in periorbital rejuvenation
   have demonstrated:
   • Statistically significant improvements in skin elasticity and dermal thickness versus baseline and HA
   controls (Lee et al., Pak et al. – split-face periocular trials).
   • Superior or equivalent performance to HA fillers for fine rhytids and skin texture, with longer duration in
   some parameters.
   • High patient and investigator satisfaction rates (>80% in multiple series) for brightness, hydration, and
   overall rejuvenation.
   • Visible clinical improvement typically begins at 2-4 weeks, peaks at 8-12 weeks post-course, and
   persists 6-12 months.
   Real-World Observations in My Practice: In over 150 patients treated with AMI Eyes (or similar PN
   formulations) since 2024, I have observed consistent brightening and smoothing effects. Patients frequently
   report looking “less tired” and “more refreshed” even when volume loss is not fully corrected. Combination
   with HA filler (staged 4-6 weeks apart) yields excellent synergistic results in patients with both skin quality
   and structural deficits.

   SAFETY PROFILE AND ADVERSE EVENTS

   Polynucleotides derived from salmon DNA have an established safety record in aesthetic and wound-healing
   applications. AMI Eyes is generally well-tolerated with a favorable risk-benefit profile for the periorbital area.
   Common, Transient Effects (typically resolve within 24-72 hours):
   • Mild to moderate erythema and edema at injection sites
   • Pinpoint ecchymosis or bruising (minimized with cannula technique)
   • Temporary tenderness or tightness sensation
   Rare or Unreported in My Experience:
   • Nodules, granulomas, or product migration (unlike some HA fillers in this area)
   • Tyndall effect or bluish discoloration
   • Vascular compromise or necrosis
   • Allergic reactions (due to high purity and biocompatibility)
   Contraindications: Active local or systemic infection, known hypersensitivity to fish-derived products or any
   component, pregnancy or breastfeeding, autoimmune disease in active flare, history of keloid scarring
   (relative), and anticoagulant therapy with high bleeding risk (relative – assess individually).

   LIMITATIONS AND CONSIDERATIONS

   • Gradual Results: Patients seeking immediate transformation may be disappointed; education on the
   biological timeline is essential.
   • Multiple Sessions: Requires commitment to a treatment course, increasing overall cost and time
   investment compared to single-session HA filler.
   • Volume Limitation: Not suitable as monotherapy for moderate-to-severe tear trough hollowing or
   significant fat pad atrophy.
   • Evidence Base: While PN class data is robust, large independent RCTs specifically on the AMI Eyes
   formulation are limited.
   • Injector Skill: Optimal outcomes depend on precise placement in the correct dermal plane; poor
   technique can reduce efficacy.
   • Cost: Course pricing may be higher than single HA treatments in some markets, though value is high for
   regenerative benefits.

   CONCLUSION AND RECOMMENDATIONS

   AMI Eyes Polynucleotide represents a meaningful advancement in the regenerative aesthetic toolkit for
   periorbital rejuvenation. Its ability to improve fundamental skin quality parameters—thickness, elasticity,
   hydration, and brightness—makes it particularly suited to the unique anatomical and aesthetic challenges of
   the under-eye area. In my practice, it has become a go-to treatment for patients who prioritize natural-looking,
   long-term skin health over quick-fix volumization.

   Recommendations:

   • Consider AMI Eyes as first-line therapy for patients with predominant skin quality concerns (thin skin,
   crepiness, vascular dark circles, fine lines).
   • Use in combination protocols (e.g., AMI Eyes course followed by staged HA filler if volume deficit
   persists) for comprehensive rejuvenation.